Diebold Nixdorf, Incorporated (DBD) — Fair Value Analysis

Base-case fair value (P50): $100.23 · Current price: $84.50 · Verdict: Undervalued

The Verdict on DBD

Our Monte Carlo simulations indicate that DIEBOLD NIXDORF INC (DBD) is currently Fairly Valued. The analysis, which factors in thousands of forward-looking scenarios, projects a median fair value (P50) of $100.23 for DBD. This compares to the current market price of $84.50, suggesting an +18.6% potential based on our P50 estimate. Despite this indicated upside, the overall verdict reflects that the current trading level falls within a reasonable range of our probabilistic fair value assessment.

How DBD stacks up against peers

While a specific sector isn't provided for direct peer comparison, DBD's operational and financial health is categorized as "average." This quality tier aligns with our "Fairly Valued" verdict, suggesting that DBD's $84.50 appropriately reflects its fundamental standing relative to a broader market context. The average quality indicates that the company maintains a stable, but not exceptional, financial and operational profile, which supports the fair valuation without pointing to significant undervaluation or overvaluation when assessed against its implied peer set. The $100.23 fair value further solidifies this position, offering +18.6% from $84.50.

What this means for investors

For investors considering DBD, the Monte Carlo analysis suggests that the current $84.50 is consistent with a fair valuation. The projected P50 fair value of $100.23 provides a clear midpoint for our probabilistic assessment, implying +18.6% from current levels. While the "average" quality tier does not suggest a compelling discount, it likewise doesn't flag significant risk of overpayment at $84.50. To gain a comprehensive understanding of DBD's valuation, including the full bear (P10) and bull (P90) distribution and the probability of achieving upside scenarios, sign up for FairCurve today.